Intralesional Methotrexate Injection for The Treatment of Epithelial Crateriform Tumor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jun Hyuk | - |
dc.contributor.author | Kim, Yoon Jae | - |
dc.contributor.author | Park, Sung Jin | - |
dc.contributor.author | Kim, Dai Hyun | - |
dc.contributor.author | Ahn, Hyo Hyun | - |
dc.contributor.author | Seo, Soo Hong | - |
dc.date.accessioned | 2023-12-13T11:31:31Z | - |
dc.date.available | 2023-12-13T11:31:31Z | - |
dc.date.issued | 202309 | - |
dc.identifier.issn | 0190-9622 | - |
dc.identifier.issn | 1097-6787 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/64740 | - |
dc.description.abstract | Intralesional methotrexate (IL-MTX) is a therapeutic method to treat Keratoacanthoma (KA), which is a representative tumor of various epithelial crateriform tumors (ECTs). However, not all of ECTs are responsive to IL-MTX treatment. We retrospectively reviewed 12 patients who received IL-MTX for the treatment of ECTs between 2015 to 2022. The effectiveness was evaluated in terms of size reduction and divided into 3 groups : Complete response (CR), partial response (PR), and no response (NR). Among twelve patients with ECT, eight patients reached to CR and four patients showed 3 NR and 1 PR individually. Nine patients underwent skin biopsy before IL-MTX treatment. Five were well differentiated squamous cell carcinoma (SCC), 2 were KA, and 2 were moderate to poorly differentiated SCC. All patients with biopsy confirmed KA experienced CR without recurrence. 60% of well differentiated SCC showed CR but 40% showed NR. In two patients with moderate to poorly differentiated SCC, one patient experienced pathological CR, and the other patient experienced PR. IL-MTX treatment can be an effective conservative therapeutic option for patients with biopsy confirmed KA and well differentiated SCC. In addition, pre-surgical IL-MTX can also be an option for SCC with unfavorable pathologic type. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Intralesional Methotrexate Injection for The Treatment of Epithelial Crateriform Tumor | - |
dc.type | Conference | - |
dc.identifier.doi | 10.1016/j.jaad.2023.07.236 | - |
dc.citation.title | Journal of the American Academy of Dermatology | - |
dc.citation.startPage | AB58 | - |
dc.citation.endPage | AB58 | - |
dc.citation.conferenceName | Annual Meeting of the American-Academy-of-Dermatology (AAD) | - |
dc.citation.conferencePlace | 미국 | - |
dc.citation.conferencePlace | New Orleans, LA, USA | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.